AOD9604

Name: AOD9604
Brand: LyoPep

Also known as AOD-9604

Modified human-growth-hormone fragment 176–191 · investigational metabolic research peptide

≥ 99.0% · target, verify batch COACAS 221231-10-3RUO

Batch COA

MOQ1 kit (10 vials) per SKU

Supplied formLinear 16-residue peptide with an added N-terminal tyrosine and an intramolecular disulfide bond

Lead time10–18 days

AOD9604 — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-batch COA

AOD9604 — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-batch COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research applications include adipocyte lipolysis and lipogenesis models, β3-adrenergic-receptor-related signaling, comparison with full-length hGH or hGH fragments, peptide degradation and disulfide-stability studies, and preclinical cartilage or tissue-remodeling models
Reported animal or historical trial observations are not approved therapeutic benefits and do not establish a current product claim.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 221231-10-3
Formula: C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular weight: 1815.1 g/mol
Appearance: Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-batch COA
Purity: ≥ 99.0% · target, verify batch COA
Storage: Follow the released lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, buffer, concentration, container and any post-reconstitution hold time require stability-indicating evidence for the exact supplied form. Do not infer storage or in-use dating from another supplier, a trial formulation or generic peptide advice.
MOQ: 1 kit (10 vials) per SKU
Lead time: 10–18 days

PubChem CID 71300630

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about AOD9604

AOD-9604 is a modified 16-residue peptide derived from the C-terminal region of human growth hormone, commonly described as hGH residues 176–191 with an added N-terminal tyrosine. It was developed as an obesity candidate and studied in several human trials. The pivotal 24-week Phase 2b OPTIONS trial did not meet its primary weight-loss endpoint, and the sponsor terminated that indication in 2007. AOD-9604 is not an FDA-approved finished drug. On 4 December 2024, the FDA Pharmacy Compounding Advisory Committee recommendation weighed against adding the free base or acetate to the 503A Bulks List. The 2026 WADA Prohibited List is in force for athletes subject to anti-doping rules. This catalogue material is RUO only.

Laboratory topics include adipocyte metabolism, β3-adrenergic-receptor biology, comparison of hGH-derived fragments, peptide degradation, disulfide integrity and preclinical cartilage or tissue-remodeling models
No approved obesity, joint, wellness or other clinical indication is established.

Mechanism context

The question the literature is testing

Preclinical studies report acute metabolic effects that may not require β3-adrenergic receptors and longer-term changes associated with β3-adrenergic-receptor expression. Other publications describe a profile distinct from full-length hGH. These mechanisms remain model-dependent: they do not prove clinically meaningful fat loss, joint repair, absence of GH-receptor signaling or lack of IGF-1 and glucose effects for every formulation or lot. Direct receptor, pathway and orthogonal comparator controls are required.

Evidence map

Research routes and exposure context

Evidence tierHuman clinical research

Research areaGrowth-hormone axis research

Routes reported in sources

SubcutaneousIntravenousOral

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not an approved finished medicine and not for human or veterinary use
Historical trial data apply only to the studied formulations, routes, populations and durations and do not establish the safety of an RUO supplier lot or community injection practice
FDA advisory materials identified characterization, aggregation, peptide-related impurity and immunogenicity concerns and recommended against 503A-list inclusion at the 4 December 2024 meeting
WADA prohibits AOD-9604 for covered athletes
Laboratory work should follow the lot SDS and institutional controls; this catalogue provides no administration, pregnancy, monitoring or adverse-event advice.

Interactions reported in the literature

No controlled evidence establishes product-specific compatibility or synergy with hyaluronic acid, GLP-1/GIP medicines, BPC-157, CJC-1295, ipamorelin, insulin or other materials in humans
A rabbit osteoarthritis experiment is animal-model context only
Experimental co-use requires a protocol-specific rationale, physical and chemical compatibility data and direct safety and pathway controls.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

AOD9604 batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

2 mg
5 mg
10 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

Define the complete sequence, N-terminal modification, termini, intramolecular disulfide connectivity, salt or counterion and formulation
Require lot traceability, theoretical and high-resolution observed intact mass, sequence-level evidence where appropriate, a stability-indicating chromatographic purity and impurity profile, quantitative peptide content, water, residual solvents, aggregation assessment where relevant and lot-specific stability
Sterility, endotoxin and bioburden are separate released-lot claims
Appearance, dissolution or HPLC area percentage alone cannot establish content, disulfide integrity, clinical suitability or safety.

Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

AOD22 mg10 vials

AOD55 mg10 vials

AOD66 mg10 vials

AOD1010 mg10 vials

Other format

Also available as a nasal spray (US stock)

Black 10 mL nasal spray bottle with a clear cap — 10 mL nasal spray bottle

Besides lyophilized vials, AOD9604 is also supplied as a nasal spray solution, shipped from our US stock.

Strengths: 2 mg · 5 mg · 10 mg
Bottle sizes: 10 mL or 20 mL
Minimum order: 10 bottles per strength and bottle size
Ships from: Our US stock

Handling

Plan storage before the parcel arrives

Follow the released lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, buffer, concentration, container and any post-reconstitution hold time require stability-indicating evidence for the exact supplied form. Do not infer storage or in-use dating from another supplier, a trial formulation or generic peptide advice.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity: PubChem CID 71300630, formula C₇₈H₁₂₃N₂₃O₂₃S₂ and molecular weight approximately 1815.1 Da. Clinical-development context: FDA Pharmacy Compounding Advisory Committee briefing materials for 4 December 2024 summarize the human program and negative 24-week Phase 2b OPTIONS result; the committee recommendation weighed against adding AOD-9604 free base or acetate to the 503A Bulks List. Stier et al. 2013 provides pooled tolerability context for studied trials but does not validate current community routes or products. Moré and Kenley 2014 reports animal/in-vitro metabolism data. Wu et al. 2015, PMID 26275694, is a rabbit osteoarthritis study, not a human trial. The 2026 WADA Prohibited List provides current anti-doping context. Consumer claims of TGA-approved iTRAM use were not accepted without a primary regulatory source.

01
Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone
Hormone Research (Karger) · 2000 · peer-reviewed original research (preclinical, rodent)
Open source
02
The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice
Endocrinology (Oxford Academic / Endocrine Society) · 2001 · peer-reviewed original research (preclinical, mechanism)
Open source
03
Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model
Annals of Clinical & Laboratory Science · 2015 · peer-reviewed original research (preclinical, rabbit model)
Open source
04
Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health
Journal of Endocrinology and Metabolism · 2014 · peer-reviewed review/summary of nonclinical toxicology and pharmacokinetic data
Open source
05
Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans
Journal of Endocrinology and Metabolism · 2013 · peer-reviewed review/pooled summary of clinical safety data
Open source
06
AOD-9604 Does Not Influence the WADA hGH Isoform Immunoassay
Drug Testing and Analysis (Wiley) · 2013 · peer-reviewed original research (analytical/anti-doping)
Open source
07
Obesity Drug Codenamed AOD9604 Highly Successful in Trials
News-Medical.net (trade/science news, sourced from company press release) · 2004 · company press release republished by trade news outlet
Open source
08
Pharmacy Compounding Advisory Committee (PCAC) Briefing Document — AOD-9604 (Free Base) and AOD-9604 (Acetate) Evaluation for 503A Bulk Drug Substances List
U.S. Food and Drug Administration · 2024 · regulatory document (FDA advisory committee briefing/evaluation)
Open source

Product FAQ

Questions buyers ask about AOD9604

What does AOD-9604's clinical-development history establish?+

AOD-9604 entered an obesity-development program and was studied in several human trials, but the pivotal 24-week Phase 2b OPTIONS study did not meet its primary weight-loss endpoint and the sponsor ended that indication in 2007. This history provides safety and pharmacology context for the studied formulations and routes; it does not make a current RUO batch an approved medicine or establish a subcutaneous, joint, weight-loss or wellness use.

Is AOD-9604 simply a smaller form of growth hormone?+

It is a modified peptide derived from the C-terminal region of human growth hormone, but published models describe a pharmacology distinct from full-length hGH. Statements about lipolysis, β3-adrenergic-receptor expression, lack of GH-receptor activity or absence of IGF-1 effects are model- and formulation-dependent; they are not proof of human efficacy or a broadly safer profile. Mechanistic experiments should use direct receptor, pathway and comparator controls.

What do FDA and WADA references mean for buyers?+

At its 4 December 2024 meeting, the FDA Pharmacy Compounding Advisory Committee recommendation weighed against adding AOD-9604 free base or acetate to the 503A Bulks List; an advisory recommendation is not marketing approval. Separately, WADA prohibits AOD-9604 for athletes subject to its rules. Neither status verifies a supplier lot, so identity, quality and intended-use controls remain separate procurement questions.

Evidence before order

AOD9604

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about AOD9604

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

AOD9604 batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Also available as a nasal spray (US stock)

Plan storage before the parcel arrives

Terms to settle before the purchase order

Literature behind the research context

Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone

The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice

Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model

Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health

Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans

AOD-9604 Does Not Influence the WADA hGH Isoform Immunoassay

Obesity Drug Codenamed AOD9604 Highly Successful in Trials

Pharmacy Compounding Advisory Committee (PCAC) Briefing Document — AOD-9604 (Free Base) and AOD-9604 (Acetate) Evaluation for 503A Bulk Drug Substances List

Questions buyers ask about AOD9604

Buyer intelligence

Compare adjacent molecules and documentation needs.

Sermorelin

Ipamorelin

GHRP-2

Tesamorelin 10mg + Ipamorelin 5mg